ranirestat
Small moleculeexperimental
Ranirestat is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT00101426)
Timeline
Indications
Mechanism of action
- Aldose reductaseINHIBITOR
AKR1B1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12- Mol. weight
- 420.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL334830 ↗
- WikipediaRanirestat ↗
- ChEMBLCHEMBL132846 ↗
Also known as
- 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1.2',3,5'-tetrone
- as 3201
- as-3201
- ranirestat
- ranirestat
- ranirestat
- ranirestat
- ranirestat
- sx 3030
- sx-3030
- sx 3202
- sx-3202
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00927914 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2009 | Eisai |
| NCT00101426 | Phase 3 | Oct 1, 2004 | Sumitomo Dainippon |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 1 | 1 | 1 | 2009 |
| Sumitomo Dainippon | For profit | 1 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1